Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 86 | SFEBES2022 | Next issue

Society for Endocrinology BES 2022

Harrogate, United Kingdom
14 Nov 2022 - 16 Nov 2022

Card image cap
SfE BES is returning to Harrogate in 2022. Join with endocrine specialists from across the UK and beyond for the Society for Endocrinology's flagship meeting.

Oral Communications

Bone and Calcium

ea0086oc1.1 | Bone and Calcium | SFEBES2022

Evaluation of efficacy and safety of a novel gene therapy drug (ARU-2801) for hypophosphatasia in non-human primates

Shadid Mohammad , Gaukel Eric , Zhao Dongwei , Miyake Noriko , Tanaka Yuusuke , Matsumoto Tae , Miyake Koichi

Objectives: Hypophosphatasia (HPP) is an inborn error of metabolism resulting from loss of function mutations in the tissue-nonspecific alkaline phosphatase (TNAP) gene. Asfotase alfa is an approved enzyme replacement therapy for HPP, while effective, it requires chronic multiple injections up to 6 times per week. We have developed a one-time gene therapy drug (ARU-2801: an adeno-associated viral vector expressing TNAP-D10) for HPP and examined the safety and effica...

ea0086oc1.2 | Bone and Calcium | SFEBES2022

Hypercalcaemic mice harbouring a germline ablation of G-protein subunit alpha-11 have anaemia that is corrected by treatment with erythropoietin

Hannan Fadil , Stevenson Mark , Kooblall Kreepa , Olesen Mie , Yon Marianne , Stewart Michelle , Wells Sara , Duncan Bassett J.H. , Williams Graham , Thakker Rajesh

G-protein subunit α-11 (Gα11), which is encoded by GNA11, plays a major role in calcium homeostasis by regulating parathyroid hormone (PTH) secretion, and germline loss-of-function mutations cause familial hypocalciuric hypercalcaemia type 2 (FHH2). Since Gα11 is ubiquitously expressed, we investigated whether FHH2 is associated with additional non-calcitropic phenotypes by analysing mice harbouring a homozygous germline deletion o...

ea0086oc1.3 | Bone and Calcium | SFEBES2022

X-linked osteoporosis caused by a novel c.892-2A>G plastin 3 (PLS3) splice variant

Connelly Paul , Talla Maria

A 24-year-old male was referred to endocrinology with multiple severe atraumatic vertebral fractures. In the preceding 10 years the patient had experienced a bimalleolar ankle fracture and numerous metacarpal and metatarsal breakages unrelated to trauma. There was no family history of osteoporosis and examination did not reveal any abnormalities in scleral colour, stature, dentition or facial/thoracic morphology. Dual-energy x-ray absorptiometry demonstrated severe densitometr...

ea0086oc1.4 | Bone and Calcium | SFEBES2022

Measurements of circulating conjugated and unconjugated vitamin D metabolites by enzyme hydrolysis combined with liquid chromatography mass spectrometry

Jenkinson Carl , Desai Reena , McLeod Malcolm , Wolf Mueller Jonathan , Hewison Martin , Handelsman David

Recent in-vitro studies have shown that vitamin D metabolites undergo conjugation reactions by sulfation and glucuronidation and may be important mechanisms for the inactivation, storage and excretion of analytes. However the circulating concentrations and clinical significance of phase II vitamin D conjugation is unclear as current analysis has almost exclusively been restricted to measuring their unconjugated metabolite forms. In this study we aimed to develop an analytical ...

ea0086oc1.5 | Bone and Calcium | SFEBES2022

Can pre-operative treatment with intravenous bisphosphonates or cinacalcet have an effect on intra-operative parathyroid hormone measurements?

Wijewickrama Piyumi S A , Chung Teng-Teng , Abdel-Aziz Tarek E , Kurzawinski Tom R

Introduction: Primary hyperparathyroidism is a common endocrine disorder, surgery is curative. Patients with severe hypercalcemia receive cinacalcet or intravenous bisphosphonates as bridging. Intra-operative-parathyroid-hormone (IOPTH) measurement improves surgical accuracy. Bisphosphonates may increase PTH, while cinacalcet reduces it. The main aim was to assess the effect of zoledronate and cinacalcet on IOPTH.Method: Patients over 15-yo who underwent...

ea0086oc1.6 | Bone and Calcium | SFEBES2022

The AXT914 calcilytic compound increases plasma calcium and PTH in a mouse model for autosomal dominant hypocalcaemia type 1 (ADH1)

Kooblall Kreepa , Hannan Fadil , Stevenson Mark , Lines Kate , Meng Xin , Stewart Michelle , Wells Sara , Gasser Jurg , Thakker Rajesh

Heterozygous germline gain-of-function mutations of the extracellular calcium-sensing receptor (CaSR), a G-protein coupled receptor (GPCR), result in autosomal dominant hypocalcaemia type 1 (ADH1), which may cause symptomatic hypocalcaemia with low circulating parathyroid hormone (PTH) concentrations and hypercalciuria. Negative allosteric CaSR modulators, known as calcilytics, rectify the gain-of-function caused by CaSR mutations and are a potential targeted therapy for ADH1....